Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$9.17 -6.1%	$12.37	$4.88 ▼ $19.58	$198.99M	N/A	85,730 shs	99,863 shs
AMLX Amylyx Pharmaceuticals	$8.50 -8.6%	$7.38	$2.05 ▼ $9.38	$757.86M	-0.46	1.11 million shs	1.39 million shs
AVBP ArriVent BioPharma	$19.35 -3.8%	$20.99	$15.47 ▼ $36.37	$784.42M	1.17	257,616 shs	129,045 shs
NAGE Niagen Bioscience	$10.10 +1.2%	$11.18	$3.10 ▼ $14.69	$805.51M	2.12	942,226 shs	609,482 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	0.00%	-9.37%	-33.54%	-6.95%	+976,999,900.00%
AMLX Amylyx Pharmaceuticals	0.00%	+16.25%	+14.11%	+75.14%	+317.04%
AVBP ArriVent BioPharma	0.00%	+2.97%	-5.05%	-1.42%	-17.14%
NAGE Niagen Bioscience	0.00%	-0.40%	+7.08%	+1.01%	+184.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AMLX Amylyx Pharmaceuticals	3.402 of 5 stars	4.5	2.0	0.0	0.0	2.1	2.5	0.6
AVBP ArriVent BioPharma	2.3154 of 5 stars	4.5	0.0	0.0	0.0	3.0	0.8	0.0
NAGE Niagen Bioscience	1.1664 of 5 stars	3.5	0.0	0.0	0.0	1.2	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AARD Aardvark Therapeutics	3.00	Buy	$32.80	257.69% Upside
AMLX Amylyx Pharmaceuticals	3.00	Buy	$11.75	38.25% Upside
AVBP ArriVent BioPharma	3.00	Buy	$39.14	102.34% Upside
NAGE Niagen Bioscience	3.00	Buy	$13.42	32.87% Upside

Current Analyst Ratings Breakdown

Latest AARD, AMLX, AVBP, and NAGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	AVBP ArriVent BioPharma	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/14/2025	AARD Aardvark Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$20.00 ➝ $19.00
8/12/2025	AVBP ArriVent BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $42.00
8/12/2025	AVBP ArriVent BioPharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $33.00
8/11/2025	NAGE Niagen Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $12.00
7/22/2025	AVBP ArriVent BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
7/10/2025	AMLX Amylyx Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$10.00
7/10/2025	AVBP ArriVent BioPharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$33.00
6/30/2025	AARD Aardvark Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
6/24/2025	AMLX Amylyx Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
AMLX Amylyx Pharmaceuticals	$87.37M	8.67	N/A	N/A	$2.40 per share	3.54
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	$7.65 per share	N/A
NAGE Niagen Bioscience	$116.30M	6.93	$0.06 per share	168.73	$0.60 per share	16.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AARD Aardvark Therapeutics	-$20.59M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
AMLX Amylyx Pharmaceuticals	-$301.74M	-$2.50	N/A	N/A	N/A	N/A	-82.48%	-70.15%	11/6/2025 (Estimated)
AVBP ArriVent BioPharma	-$80.49M	-$4.02	N/A	N/A	N/A	N/A	-55.40%	-51.97%	11/13/2025 (Estimated)
NAGE Niagen Bioscience	$8.55M	$0.21	48.10	∞	N/A	15.24%	23.12%	15.53%	N/A

Latest AARD, AMLX, AVBP, and NAGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	AARD Aardvark Therapeutics	-$0.52	-$0.66	-$0.14	-$0.66	N/A	N/A
8/11/2025	Q2 2025	AVBP ArriVent BioPharma	-$0.70	-$0.90	-$0.20	-$0.90	N/A	N/A
8/7/2025	Q2 2025	AMLX Amylyx Pharmaceuticals	-$0.44	-$0.46	-$0.02	-$0.46	N/A	N/A
8/6/2025	Q2 2025	NAGE Niagen Bioscience	$0.02	$0.04	+$0.02	$0.04	$28.55 million	$31.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
NAGE Niagen Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AARD Aardvark Therapeutics	N/A	14.04	14.04
AMLX Amylyx Pharmaceuticals	N/A	8.72	8.72
AVBP ArriVent BioPharma	N/A	12.74	12.74
NAGE Niagen Bioscience	N/A	3.88	3.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AARD Aardvark Therapeutics	N/A
AMLX Amylyx Pharmaceuticals	95.84%
AVBP ArriVent BioPharma	9.48%
NAGE Niagen Bioscience	15.41%

Insider Ownership

Company	Insider Ownership
AARD Aardvark Therapeutics	N/A
AMLX Amylyx Pharmaceuticals	12.30%
AVBP ArriVent BioPharma	18.58%
NAGE Niagen Bioscience	9.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AARD Aardvark Therapeutics	18	21.70 million	N/A	N/A
AMLX Amylyx Pharmaceuticals	200	89.17 million	78.20 million	Optionable
AVBP ArriVent BioPharma	40	40.57 million	33.03 million	N/A
NAGE Niagen Bioscience	120	79.75 million	72.26 million	N/A

AARD, AMLX, AVBP, and NAGE Headlines

Recent News About These Companies

Niagen Bioscience (NASDAQ:NAGE) Rating Lowered to Buy at Wall Street Zen

August 25 at 2:39 AM | americanbankingnews.com

Niagen Bioscience, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 19, 2025 | seekingalpha.com

Niagen Bioscience (NASDAQ:NAGE) Raised to "Strong-Buy" at Wall Street Zen

August 18, 2025 | americanbankingnews.com

Unlocking Cellular Health With Science and Trust

August 17, 2025 | latimes.com

Niagen Bioscience (NASDAQ:NAGE) Rating Increased to Strong-Buy at Wall Street Zen

August 17, 2025 | marketbeat.com

HC Wainwright Expects Reduced Earnings for Niagen Bioscience

August 16, 2025 | marketbeat.com

HC Wainwright Has Negative Outlook for NAGE Q3 Earnings

August 16, 2025 | americanbankingnews.com

HC Wainwright Issues Optimistic Outlook for NAGE Earnings

August 15, 2025 | marketbeat.com

Niagen Bioscience (NASDAQ:NAGE) Price Target Raised to $12.00

August 14, 2025 | americanbankingnews.com

Niagen: Imminent Trigger For A Significant Move Up (Technical Analysis)

August 13, 2025 | seekingalpha.com

Statutory Profit Doesn't Reflect How Good Niagen Bioscience's (NASDAQ:NAGE) Earnings Are

August 13, 2025 | finance.yahoo.com

Niagen Bioscience (NASDAQ:NAGE) Given New $12.00 Price Target at HC Wainwright

August 12, 2025 | marketbeat.com

Q2 EPS Forecast for Niagen Bioscience Increased by Analyst

August 12, 2025 | marketbeat.com

Breaking Down Niagen Bioscience: 4 Analysts Share Their Views

August 11, 2025 | benzinga.com

Roth Capital Cuts Earnings Estimates for Niagen Bioscience

August 9, 2025 | marketbeat.com

Earnings Beat: Niagen Bioscience, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

August 8, 2025 | finance.yahoo.com

Niagen Bioscience (NASDAQ:NAGE) Shares Gap Up Following Strong Earnings

August 8, 2025 | marketbeat.com

Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Average Recommendation of "Buy" by Brokerages

August 8, 2025 | marketbeat.com

Niagen Bioscience Reports Strong Q2 Sales Growth

August 6, 2025 | msn.com

Niagen Bioscience Inc (NAGE) Q2 2025: Everything You Need To Know Ahead Of Earnings

August 6, 2025 | finance.yahoo.com

Niagen Bioscience: Q2 Earnings Snapshot

August 6, 2025 | timesunion.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

AARD, AMLX, AVBP, and NAGE Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

$9.17 -0.60 (-6.14%)

As of 03:31 PM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Amylyx Pharmaceuticals NASDAQ:AMLX

$8.50 -0.80 (-8.61%)

As of 03:49 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

ArriVent BioPharma NASDAQ:AVBP

$19.34 -0.77 (-3.80%)

As of 03:49 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Niagen Bioscience NASDAQ:NAGE

$10.10 +0.12 (+1.20%)

As of 03:28 PM Eastern

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time